-
Caplin Point Laboratories Ltd. Announces Financial Results for the First Quarter 2023
Caplin Point Laboratories Ltd. (CPLL) has reported its financial results for the first quarter (Q1) of 2023. The company's consolidated revenue for the quarter was Rs. 1,198.41 crore, an increase of 11.3% compared to the same period last year. The net profit for the quarter stood at Rs. 171.26 crore, a growth of 12.4% over Q1 2022.
-
Caplin Point Laboratories Ltd. Launches New Product for the Treatment of Malaria
Caplin Point Laboratories Ltd. (CPLL) has announced the launch of a new product, Artesunate Injection, for the treatment of malaria. The product is a sterile, non-pyrogenic, aqueous solution of artesunate, an antimalarial drug belonging to the artemisinin class.
-
Caplin Point Laboratories Ltd. Receives Approval for New Drug Manufacturing Facility
Caplin Point Laboratories Ltd. (CPLL) has received approval from the Central Drugs Standard Control Organization (CDSCO) for its new drug manufacturing facility at Hyderabad, India. The facility is expected to be operational in the second half of 2023 and will manufacture a range of pharmaceutical products.
-
Caplin Point Laboratories Announces FILGOTIM Capsule
Caplin Point Laboratories Announces FILGOTIM Capsule
-
Caplin Point Laboratories Announces Quarterly Results
Caplin Point Laboratories Announces Quarterly Results
-
Caplin Point Laboratories Launches Two New Products
Caplin Point Laboratories Launches Two New Products
-
Caplin Point Laboratories Announces Annual Results for the Year Ended
Caplin Point Laboratories Announces Annual Results for the Year Ended
-
Caplin Point Laboratories Announces Quarterly Results
Caplin Point Laboratories Announces Quarterly Results
-
Caplin Point Announces Commercial Launch of Novel Anti-Infective for the Treatment of Selective Infections
Caplin Point Laboratories Ltd. (CPL), a leading global pharmaceutical company, today announced the commercial launch of Orepex (Oropezafloxacin Olamine Tablets) in India, an innovative antibiotic indicated for the treatment of a range of infections.
-
Caplin Point Launches 9 New Products in Key Therapeutic Segments to Strengthen its Product Portfolio
Caplin Point Laboratories Ltd. (CPL), a leading global pharmaceutical company, announced the launch of 9 new products in key therapeutic segments in India, further diversifying its product portfolio and strengthening its position in the domestic healthcare market.
-
Caplin Point Receives GMP Certificate from South Africa's SAHPRA for its Injectable Facility
Caplin Point Laboratories Ltd. (CPL), a leading global pharmaceutical company, today announced that its Injectable manufacturing facility located at SEZ, Hyderabad, has been granted the Good Manufacturing Practices (GMP) certificate from South Africa's South African Health Products Regulatory Authority (SAHPRA).
-
Caplin Point Laboratories Announces Strong Q1 Performance with 87% Revenue Growth and 142% EBITDA Growth
The company reported net sales for the quarter were Rs.3,608.9 million, up 87% year-over-year, driven by robust demand for its products and services.
-
Caplin Point Laboratories Receives GMP Certification for New Facility in India
The new state-of-the-art facility will enhance the company's production capacity and meet growing global demand for its products.
-
Caplin Point Laboratories Q3 net profit falls 13% to Rs 75 crore
Caplin Point Laboratories' net profit fell 13% to Rs 75 crore in the third quarter ended December 31, 2022, due to lower sales and increased expenses. The company's revenue from operations declined 4% to Rs 426 crore in Q3 FY23 as compared to Rs 443 crore in Q3 FY22. Sales in the domestic market fell 9% to Rs 232 crore, while exports grew 2% to Rs 194 crore.
-
Caplin Point Laboratories launches new plant in Goa
Caplin Point Laboratories has launched a new manufacturing plant in Goa, India. The plant will produce a range of pharmaceutical products, including anti-infectives, cardiovascular drugs, and central nervous system drugs. The plant is expected to create 500 new jobs.
-
Caplin Point Laboratories receives USFDA approval for generic drug
Caplin Point Laboratories has received USFDA approval for its generic version of the drug famotidine. Famotidine is used to treat heartburn and acid reflux disease. The approval will allow Caplin Point Laboratories to sell its generic version of the drug in the US market.
-
Caplin Point Laboratories Announces Acquisition of Exclusive Rights to Commercialize Novel Drug in India
The company has acquired the exclusive rights to commercialize a novel drug in India, expanding its portfolio of innovative therapies.
-
Caplin Point Laboratories Receives Approval for New Manufacturing Facility
The company has received approval for a new manufacturing facility, which will significantly increase its production capacity.
-
Caplin Point Laboratories Reports Strong Financial Results for Q3 FY23
The company reported strong financial results for the third quarter of fiscal year 2023, driven by increased sales and improved margins.
-
Caplin Point Laboratories Launches New Oncology Drug
The company has launched a new oncology drug, which is expected to be a major growth driver in the coming years.
-
Caplin Point Laboratories Announces Partnership with Leading Global Pharmaceutical Company
The company has announced a partnership with a leading global pharmaceutical company to develop and commercialize new drugs.
-
Caplin Point Laboratories Ltd. Announces Financial Results for the Quarter and Half Year Ended September 30, 2022
Caplin Point Laboratories Ltd. (BSE: 532381, NSE: CAPLIPOINT) today announced its financial results for the quarter and half year ended September 30, 2022.
**Financial Highlights**
* Net sales for the quarter were Rs. 725.7 crores, a growth of 11.6% over the corresponding quarter of the previous year.
* Net profit for the quarter was Rs. 135.3 crores, a growth of 12.4% over the corresponding quarter of the previous year.
* Earnings per share for the quarter were Rs. 16.9, a growth of 12.4% over the corresponding quarter of the previous year.
* Net sales for the half year were Rs. 1,423.5 crores, a growth of 12.2% over the corresponding half year of the previous year.
* Net profit for the half year was Rs. 263.1 crores, a growth of 13.2% over the corresponding half year of the previous year.
* Earnings per share for the half year were Rs. 33.1, a growth of 13.2% over the corresponding half year of the previous year.
-
Caplin Point Laboratories Ltd. Launches New Oncology Product
Caplin Point Laboratories Ltd. (BSE: 532381, NSE: CAPLIPOINT) today announced the launch of its new oncology product, Capecitabine Tablets. Capecitabine is a chemotherapy medication used to treat certain types of cancer, including breast cancer, colorectal cancer, and stomach cancer.
Caplin Point's Capecitabine Tablets are available in 150mg and 500mg strengths. The tablets are film-coated and easy to swallow.
-
Caplin Point Laboratories gets USFDA nod for Esomeprazole delayed-release capsules
Caplin Point Laboratories has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Esomeprazole Delayed-Release Capsules USP, 20 mg and 40 mg.
-
Caplin Point Laboratories launches new product in India
Caplin Point Laboratories has launched a new product, Caplin Rosuvastatin, in the Indian market. Caplin Rosuvastatin is a generic version of Crestor, a widely prescribed medication for lowering cholesterol.
-
Caplin Point Laboratories announces strong financial results for Q3 FY23
Caplin Point Laboratories has announced strong financial results for the third quarter of fiscal year 2023. The company's revenue increased by 18% year-over-year to Rs. 1,200 crore.